You and a friend both take estradiol for hot flashes. She swallows a pill each morning. You wear a patch and change it twice a week. Same hormone, same goal, so why the different delivery? The route is not a cosmetic detail. It changes how the drug moves through your body, and that changes your risk of a blood clot. This is the most consequential choice you will make about hormone therapy after deciding to start it.
There are three common ways to deliver systemic estradiol: a skin patch, a gel or spray you rub on, and a tablet you swallow. The patch and gel are grouped together as transdermal, meaning through the skin. The pill is oral. The difference between transdermal and oral is where the story is.
The First-Pass Problem With Pills
When you swallow an estrogen tablet, it goes to your gut, gets absorbed, and travels straight to the liver before it reaches the rest of your body. This is called first-pass hepatic metabolism. Every oral drug goes through it, but with estrogen the liver step has a specific consequence. The liver responds to that concentrated estrogen load by ramping up production of clotting factors.
The result is a measurable increase in the risk of venous thromboembolism, the umbrella term for deep vein clots in the leg (DVT) and clots that travel to the lung (PE). Oral estrogen also nudges triglycerides upward and raises a protein called C-reactive protein, both markers tied to vascular risk.
A patch or gel skips this. Estradiol crosses the skin and enters the bloodstream directly, so it reaches the liver at the same low concentration as the rest of your tissues. There is no first-pass surge, and the clotting-factor effect is largely avoided.
What the Clot Data Actually Show
This is not a theoretical concern. Large observational studies have measured it. Analyses of UK primary care records, including work drawing on the QResearch and CPRD databases (Vinogradova et al., BMJ 2019), found that oral estrogen carried a higher risk of venous thromboembolism than no treatment, while transdermal estradiol did not show a meaningful increase in clot risk even though it treats the same symptoms.
The Menopause Society's 2022 Hormone Therapy Position Statement reflects this directly. It names transdermal estradiol as the preferred route for women who have a higher baseline clot risk, including women with obesity, a personal or family clotting history, or other vascular risk factors. For a woman with no special risk who wants a pill, oral estradiol is still a reasonable option. The route is a risk-tiering decision, not a one-size rule.
Patch vs Gel: Both Transdermal, Slightly Different in Practice
If you have decided on the transdermal route, the patch and gel deliver the same clot advantage. The choice between them comes down to how they fit your life.
The patch
A small adhesive patch worn on the lower abdomen or buttock, changed once or twice a week depending on the product. It gives steady levels with no daily step. The downsides are skin irritation at the application site for some people, and the patch edges peeling with heat, sweat, or swimming. Doses run in a familiar range, often 0.025 to 0.1 mg per day, and titrating up or down is straightforward.
The gel or spray
A measured amount of gel or a spray applied to the skin daily, usually the arm or thigh. It lets you fine-tune the dose and avoids the adhesive problem. The tradeoffs are a daily application step, a drying time before you dress, and a transfer risk: you must keep the treated skin from contacting another person, especially children, until it dries. Some women prefer the gel simply because nothing is stuck to them.
Neither is clinically better than the other for symptom relief or for clot risk. Pick the one you will actually use as directed.
When the Pill Still Makes Sense
Oral estradiol is not banned. For a healthy woman in her early 50s with no clotting history, no obesity, no migraine with aura, and a preference for a pill, the absolute clot risk on oral estrogen is still low. Some women find a daily tablet easier to remember than a twice-weekly patch. The point is informed choice. If you carry extra clot risk, transdermal is the safer route and most guidelines will steer you there. If you do not, the pill is on the table.
There is one more wrinkle. Migraine with aura raises stroke risk on its own, and oral estrogen can add to that. For women with aura, the transdermal route at a low dose is generally preferred, and this is a conversation to have explicitly with your clinician.
The Progesterone Reminder
Whatever route you choose for estrogen, the rule about the uterus does not change. If you still have your uterus and take systemic estradiol by any route, you also need a progestogen, usually oral micronized progesterone, to protect the uterine lining from overgrowth. Patch, gel and pill are all systemic estrogen, so all three require this pairing. The only women who take estrogen alone are those who have had a hysterectomy.
How to Have the Conversation
Walk into your visit with three facts ready: whether you or close family have ever had a blood clot, stroke, or heart attack, whether you get migraines with aura, and how you feel about a daily step versus a twice-weekly one. Those three answers point clearly toward patch, gel, or pill. Your clinician will weigh your full history, but you can shape the decision by knowing what drives it.
The headline is simple. The patch and gel lower clot risk by skipping the liver. The pill is reasonable for low-risk women who prefer it. The hormone is the same. The route is where your risk profile gets to weigh in.
Reviewed By
[Reviewed by: clinician name, credential. Last reviewed: date.]
Not sure which route fits your history? Start an intake and a licensed clinician will review your clot and cardiovascular risk and recommend a patch, gel or pill.
This article is for education and is not a substitute for individual medical advice from your own clinician.